Ryan N. Kaiser

I'll research this attorney before drafting.

Let me dig deeper into specific cases and any PTAB/Federal Circuit work.

Ryan N. Kaiser — Patent Litigation Practice Summary

Focus areas. Kaiser is an associate in the Trial & Appellate Practice Group at Sterne, Kessler, Goldstein & Fox, where his practice centers on patent litigation in the federal district courts, the U.S. International Trade Commission, and the Federal Circuit, per the firm's professional bio. His publicly visible matters are technologically mixed rather than concentrated in one field: 3D vision-guided robotics and industrial software (RoboticVISIONTech v. ABB), genomic sequencing and diagnostics (TwinStrand Biosciences v. Guardant Health), and pharmaceutical/Hatch-Waxman work (Corcept v. Teva; the tracked Unified Patents–Breckenridge Pharmaceutical matter). I found no sourced indication of Wi-Fi/standards-essential, mechanical, or other standards-based work.

Side preference. The tracked data (1 plaintiff-side, 2 defendant-side appearances) is consistent with the public docket record, which shows him working both sides: enforcement for patent-owning operating companies (TwinStrand Biosciences and the University of Washington; RoboticVISIONTech against ABB) and defense of accused infringers (Teva in an ANDA litigation). Nothing in the sourced record suggests a PAE/NPE-focused practice; his plaintiff-side clients appear to be operating companies and a university licensee. Note that two of the three tracked appearances are untitled in the underlying data, which limits any firm conclusion about a side preference.

Firm context. Kaiser has been at Sterne Kessler since 2017, initially as an IP Assistant, and was previously at a litigation boutique handling intellectual property matters (the firm does not name it). There is no indication he has been in-house.

Notable matters. (i) TwinStrand Biosciences, Inc. v. Guardant Health — Sterne Kessler obtained an $83.4 million jury verdict in November 2023 on two University of Washington–owned sequencing patents, with findings of willful infringement; Kaiser is listed among the associates on the trial team. (ii) Corcept Therapeutics v. Teva Pharmaceuticals (D.N.J.) — December 2023 non-infringement ruling for Teva on mifepristone method-of-use patents; Kaiser is listed on the team. (iii) RoboticVISIONTech, Inc. v. ABB Inc. (D. Del., Nos. 1:22-cv-01257 and 1:24-cv-00589) — patent, copyright, and trade-secret claims consolidated and resolved by settlement and dismissal in March 2025. In all three, published firm announcements list him as part of a larger team led by firm directors, not as lead counsel.

PTAB / IPR experience. He was on the Sterne Kessler team that secured denial of institution of ABB's IPR2023-01426 against a RoboticVISIONTech patent. The record I located shows him as PTAB-adjacent rather than as a frequent first-chair petitioner or patent-owner counsel; I did not find a substantial standalone IPR docket under his name.

Bar / education. Admitted in the District of Columbia; J.D., American University Washington College of Law (magna cum laude); B.A., University of South Carolina. The bio does not indicate registration as a patent attorney before the USPTO. Disambiguation: a different attorney, Ryan M. Kaiser of Kaiser IP, LLC (Illinois), practices trademark and regulatory work and should not be conflated with this profile.